An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms Accordance-OLE
- Sponsors Intec Pharma
- 03 Dec 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2019.
- 03 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2019.
- 29 Mar 2017 According to an Intec Pharma media release, status changed from not yet recruiting to recruiting.